← Back to diffwire
India launches 50+ generic Semaglutides as patents expire, prices to drop
8 articles |
Updated 1d ago |
Created 2d ago
The patent on Novo Nordisk's blockbuster semaglitide drugs has expired in just two days following the March deadline. This development triggers an immediate launch storm with more than fifty Indian pharmaceutical brands entering a competitive market for generic versions of Ozempic and Wegovy, potentially driving global prices down by over 50 percent within months as reported on Friday morning (March 18). While this seismic shift promises to reshape access to weight-loss treatment worldwide after years of high costs in the US.
Key Points
-
1[Mar 18] The patent on semaglutide, active ingredient for global obesity treatments like Novo Nordisk's Ozempic and Wegovy, is expiring in India.
-
2India plans to launch over 50 new brands of cheap weight-loss drugs following this expiry event known as the 'patent cliff'.
-
3[Mar 18] Experts warn that while these generic versions could drastically lower costs by more than half globally (upwards), safety and regulatory questions remain.
-
4This development is expected to reshape global obesity treatment access, potentially making life-saving drugs significantly cheaper for patients worldwide.
Developments
[Mar 18]
India's patent on semaglutide expires in the country (specifically noted as expiring 'in two days' relative to Mar 06:59 report).
[Mar 17] - [Feb/Mar timeframe implied]
Danish drugmaker Novo Nordisk's blockbuster drugs Wegovy and Ozempic utilize the semaglutide molecule.
Kraj skupog Ozempica? Ističe patent, stižu jeftine verzije iz Indije, cijene bi mogle pasti za više od 50 posto
Slobodnadalmacija.hr
2d ago
Kraj skupog Ozempica? Istječe patent, stižu jeftine verzije iz Indije, cijene bi mogle pasti za više od 50 posto
Slobodnadalmacija.hr
2d ago